within Pharmacolibrary.Drugs.ATC.R;

model R03AL09
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00025,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03AL09</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>A fixed triple combination inhalation therapy consisting of formoterol (a long-acting beta-2 adrenergic agonist), glycopyrronium bromide (a long-acting muscarinic antagonist), and beclometasone (an inhaled corticosteroid) used for maintenance treatment of asthma and COPD in adults when combination therapy is appropriate. Approved and marketed for use in the EU and various other countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic estimates for healthy adult individuals after inhalation; no direct published clinical population PK studies exist for the triple fixed-dose combination. Model parameters are estimated based on available summary pharmacokinetics for each component in fixed-dose combination inhalers.</p><h4>References</h4><ol><li><p>Kuna, P, et al., &amp; Ciurlia, G (2022). Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma. <i>Pharmacology research &amp; perspectives</i> 10(4) e980–None. DOI:<a href=&quot;https://doi.org/10.1002/prp2.980&quot;>10.1002/prp2.980</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35733414/&quot;>https://pubmed.ncbi.nlm.nih.gov/35733414</a></p></li><li><p>Rony, F, et al., &amp; Klein, J (2024). Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurised metered-dose inhaler using a low global warming potential propellant. <i>Pulmonary pharmacology &amp; therapeutics</i> 85 102299–None. DOI:<a href=&quot;https://doi.org/10.1016/j.pupt.2024.102299&quot;>10.1016/j.pupt.2024.102299</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38663512/&quot;>https://pubmed.ncbi.nlm.nih.gov/38663512</a></p></li><li><p>Kupczyk, M, &amp; Kuna, P (2019). Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide as a combination therapy for chronic obstructive pulmonary disease. <i>Expert review of respiratory medicine</i> 13(1) 5–11. DOI:<a href=&quot;https://doi.org/10.1080/17476348.2019.1548937&quot;>10.1080/17476348.2019.1548937</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30463457/&quot;>https://pubmed.ncbi.nlm.nih.gov/30463457</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03AL09;
